Vion Pharmaceuticals, Inc.

New Haven, CT 06511

SBIR Award Summary

Total Number of Awards 12
Total Value of Awards $1.42MM
First Award Date 09/30/96
Most Recent Award Date 09/15/03

Key Personnel

Last Name Name Awards Contact
Doyle Terrence William Doyle 3
Bermudes David G Bermudes 3
King Ivan King 3
Lin Xu K Lin 1
Belcourt Michael F Belcourt 1
Chen Chang-Hung Chen 1

12 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/03 - 06/15/04

DESCRIPTION (provided by applicant): Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone is a novel ribonucleotide reductase inhibitor with antineoplastic activity that is 1000 times more potent than hydroxyurea as an inhibitor of ribonucleotide reductase with activity against cell lines resistant to hydroxyurea and gemcitabine. Hydrox...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/03 - 07/31/03

DESCRIPTION (provided by applicant): Attenuated Salmonella typhimurium accumulated and multiplied preferentially in tumors as compared to in normal tissues after being injected intravenously into tumor-bearing mice and rats. VNP20009, an attenuated strain with msbB-purl- deletions, is being evaluated in Phase I trials in cancer patients. VNP200...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/09/02 - 01/31/03

DESCRIPTION (provided by applicant): Salmonella are under development as anticancer vectors. In mice, attenuated Salmonella injected intravenously or intratumorally multiply preferentially within tumors, suppress tumor growth and prolong survival. One strain, VNP20009, is currently in human Phase I clinical trials. A key mutation in VNP20009, a...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/02 - 02/28/03
PI: Ivan King

The principal focus of this proposal is to explore the feasibility of using Salmonella to deliver EGF peptide antagonist to solid tumors as an anti- tumor agent. Small peptides that inhibit the activity of growth factor ligands have recently attracted significant interest in cancer therapy. As a result of the discovery of tumor-targeting Salmone...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/01 - 03/31/02
PI: Xu K Lin

DESCRIPTION (provided by applicant): 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylaminocarbonyl) hydrazine (101M) is an alkylating agent that is cytotoxic to cancer cells. Various alkylating agents are approved for the treatment of cancer including cycloph...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/01/01 - 12/31/01
PI: Ivan King

The goal of this study is to enhance the anti-tumor activity of VNP2OOO9, a genetically engineered Salmonella typhimurium, by arming the bacteria with cytokines and prod rug converting enzymes. IL2, TRAIL, DT- diaphorase, cytochrome p450 2B1, or cytosine deaminase will be cloned and expressed in VNP2OOO9 and anti-tumor activity of these clones w...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/05/00 - 01/05/01

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/06/00 - 12/31/00
PI: Ivan King

The goal of this study is to enhance the anti-tumor activity of VNP2OOO9, a genetically engineered Salmonella typhimurium, by arming the bacteria with cytokines and prod rug converting enzymes. IL2, TRAIL, DT- diaphorase, cytochrome p450 2B1, or cytosine deaminase will be cloned and expressed in VNP2OOO9 and anti-tumor activity of these clones w...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/99 - 04/30/00

The main objective of the phase II investigation is the further in-depth evaluation of three newly synthesized phosphate or disulfide containing water-soluble prodrugs of Triapine TM and further evaluation of the parent drug itself. These include more extensive prodrug bioconversion studies both in vitro a...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/98 - 04/30/99

The main objective of the phase II investigation is the further in-depth evaluation of three newly synthesized phosphate or disulfide containing water-soluble prodrugs of Triapine TM and further evaluation of the parent drug itself. These include more extensive prodrug bioconversion studies both in vitro a...

Load More